

CNS Drugs™

2002, Vol. 16, No. 10 (pp. 653-720)
ISSN: 1172-7047

Adis Spotlight
Rizatriptan

Current Opinion
Duration of Therapy for Tobacco Dependence

Therapy in Practice
HIV-Related Movement Disorders

Review Articles
Basic Pharmacology of Valproate
Clinical Experience with Valproate

PHARMACY LIBRARY
UNIVERSITY OF WISCONSIN

OCT 16 2002

Madison, WI 53705

Available Online

adis
INTERNATIONAL
A Wolters Kluwer Company

AUCKLAND • BARCELONA • BUENOS AIRES • CHESTER • HONG KONG • MADRID
MILAN • MUNICH • OSAKA • PARIS • PHILADELPHIA • SÃO PAULO • SYDNEY

PAR1033
IPR of U.S. Patent No. 8,772,306
Page 1 of 28

International Editorial Board

A.C. Altamura, *Milan, Italy*
 M. Ansseau, *Leige, Belgium*
 R.J. Baldessarini, *Belmont, MA, USA*
 P. Bech, *Hillerød, Denmark*
 M. Bialer, *Jerusalem, Israel*
 J. Biller, *Indianapolis, IN, USA*
 H. Brodaty, *Randwick, NSW, Australia*
 M.J. Brodie, *Glasgow, Scotland*
 G.D. Burrows, *Heidelberg, VIC, Australia*
 M.C. Chamberlain, *Los Angeles, CA, USA*
 D.S. Charney, *Bethesda, MD, USA*
 J.A. den Boer, *Groningen, The Netherlands*
 G.A. Donnan, *Heidelberg, VIC, Australia*
 M.J. Eadle, *Brisbane, QLD, Australia*
 H.M. Emrich, *Hanover, Germany*
 M.R. Farlow, *Indianapolis, IN, USA*
 G.A. Fava, *Bologna, Italy*
 W.W. Fleischhacker, *Innsbruck, Austria*
 D.J. Greenblatt, *Boston, MA, USA*
 C. Guilleminault, *Stanford, CA, USA*
 I. Hindmarch, *Godalming, England*
 M.W. Jann, *Atlanta, GA, USA*
 F.J. Jiménez-Jiménez, *Madrid, Spain*
 H. Kaiya, *Tokyo, Japan*
 R. Kerwin, *London, England*
 S.P. Kutcher, *Halifax, NS, Canada*
 M. Lader, *London, England*
 J.P. Larsen, *Stavanger, Norway*
 B. Leonard, *Galway, Ireland*
 E. Perucca, *Pavia, Italy*
 R.M. Post, *Bethesda, MD, USA*
 A.M. Rapoport, *Stamford, CT, USA*
 D.A. Revicki, *Bethesda, MD, USA*
 K.L. Roos, *Indianapolis, IN, USA*
 J.F. Rosenbaum, *Boston, MA, USA*
 J.W. Sander, *Chalfont St. Peter, England*
 S.C. Schachter, *Boston, MA, USA*
 S.A. Schug, *Perth, WA, Australia*
 I. Shoulson, *Rochester, NY, USA*
 S.D. Silberstein, *Philadelphia, PA, USA*

Aim and Scope: *CNS Drugs* promotes rational pharmacotherapy and effective patient management within the disciplines of clinical psychiatry and neurology by providing a regular programme of review articles covering important issues in the management of psychiatric and neurological disorders.

The Journal includes:

- Leading/current opinion articles providing an overview of contentious or emerging issues.
- Definitive reviews on approaches to the management of neurological and psychiatric illnesses.
- Therapy in Practice reviews providing practical recommendations for specific clinical situations.
- Adis Drug Evaluations reviewing the properties and place in therapy of both newer and established drugs.
- Adis New Product Profile Series reviewing innovations in diagnosis and therapy with expert commentaries.
- Original research articles will also be considered for publication. All manuscripts are subject to peer review by international experts. Letters to the Editor are welcomed and will be considered for publication.

Editor: Katharine J. Palmer

Publication Manager: Sarah N. Carson

Editorial Office and Inquiries: Adis International Ltd, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand. Information on the preparation of manuscripts will be provided to authors.

E-mail: cnsdrugs@adis.co.nz

<http://www.adis.com/cnsdrugs>

CNS Drugs (ISSN 1172-7047) will be published as 1 volume with 15 issues by Adis International Limited from 2003. Annual 2003 institutional subscription price: \$US1725. Personal subscription rate: \$US195. Subscription orders must be prepaid. All subscriptions to Adis titles include electronic access at no extra cost. (Further subscription information is given at the back of each issue.)

Policy Statement: Although great care has been taken in compiling the content of this publication, the publisher and its servants are not responsible or in any way liable for the currency of the information, for any errors, omissions or inaccuracies, or for any consequences arising therefrom. Inclusion or exclusion of any product does not imply its use is either advocated or rejected. Use of trade names is for product identification only and does not imply endorsement. Opinions expressed do not necessarily reflect the views of the Publisher, Editor or Editorial Board.

Copyright: © 2002 Adis International Ltd. All rights reserved throughout the world and in all languages. No part of this publication may be reproduced, transmitted or stored in any form or by any means either mechanical or electronic, including photocopying, recording, or through an information storage and retrieval system, without the written permission of the copyright holder.

The appearance of the code at the top of the first page of an article in this journal indicates the copyright owner's consent that copies of the article may be made for the personal or internal use of specific clients. This consent is given provided that the fee of \$US25 per copy is paid directly to the Copyright Clearance Center Inc., 222 Rosewood Drive, Danvers, Massachusetts 01923, USA, for copying beyond that permitted by sections 107 or 108 of the US Copyright Law. This consent does not extend to other kinds of copying such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale.

Basic Pharmacology of Valproate

A Review After 35 Years of Clinical Use for the Treatment of Epilepsy

Wolfgang Löscher

Department of Pharmacology, School of Veterinary Medicine, Toxicology and Pharmacy, Hannover, Germany

Contents

Abstract	669
1. Historical Background	670
2. Overview of Clinical Use	670
3. Epilepsy and Epileptic Seizures	671
4. Animal Models of Epilepsy	672
5. Effects in Experimental Models of Epilepsy and Epileptic Seizures	672
5.1 Early versus Late Effects	674
5.2 Antiepileptogenic and Neuroprotective Effects	674
5.3 Proconvulsant Effects	674
5.4 Other Pharmacodynamic Effects	675
5.5 Pharmacokinetic and Pharmacodynamic Issues	675
6. Effects on Epileptiform Discharges in <i>In Vitro</i> and <i>In Vivo</i> Preparations	676
7. Mechanisms of Action	678
7.1 Effects on Excitability or Inhibition	678
7.2 Effects on Ion Channels	679
7.2.1 Sodium Channels	680
7.2.2 Potassium Channels	680
7.2.3 Calcium Channels	680
7.3 Biochemical Effects	681
7.3.1 Effects on the γ -Aminobutyric Acid (GABA) System	681
7.3.2 Effects on γ -Hydroxybutyrate, Glutamate and Aspartate	686
7.3.3 Effects on Serotonin and Dopamine	687
7.3.4 Other Biochemical Effects	687
8. Possible Explanations for the Early and Late Effects	688
9. Conclusions	689

Abstract

Since its first marketing as an antiepileptic drug (AED) 35 years ago in France, valproate has become established worldwide as one of the most widely used AEDs in the treatment of both generalised and partial seizures in adults and children. The broad spectrum of antiepileptic efficacy of valproate is reflected in preclinical *in vivo* and *in vitro* models, including a variety of animal models of seizures or epilepsy.

There is no single mechanism of action of valproate that can completely account for the numerous effects of the drug on neuronal tissue and its broad clinical

PAR1033
IPR of U.S. Patent No. 8,772,306
Page 3 of 28

activity in epilepsy and other brain diseases. In view of the diverse molecular and cellular events that underlie different seizure types, the combination of several neurochemical and neurophysiological mechanisms in a single drug molecule might explain the broad antiepileptic efficacy of valproate. Furthermore, by acting on diverse regional targets thought to be involved in the generation and propagation of seizures, valproate may antagonise epileptic activity at several steps of its organisation.

There is now ample experimental evidence that valproate increases turnover of γ -aminobutyric acid (GABA) and thereby potentiates GABAergic functions in some specific brain regions thought to be involved in the control of seizure generation and propagation. Furthermore, the effect of valproate on neuronal excitation mediated by the *N*-methyl-D-aspartate (NMDA) subtype of glutamate receptors might be important for its anticonvulsant effects. Acting to alter the balance of inhibition and excitation through multiple mechanisms is clearly an advantage for valproate and probably contributes to its broad spectrum of clinical effects.

Although the GABAergic potentiation and glutamate/NMDA inhibition could be a likely explanation for the anticonvulsant action on focal and generalised convulsive seizures, they do not explain the effect of valproate on nonconvulsive seizures, such as absences. In this respect, the reduction of γ -hydroxybutyrate (GHB) release reported for valproate could be of interest, because GHB has been suggested to play a critical role in the modulation of absence seizures.

Although it is often proposed that blockade of voltage-dependent sodium currents is an important mechanism of antiepileptic action of valproate, the exact role played by this mechanism of action at therapeutically relevant concentrations in the mammalian brain is not clearly elucidated.

By the experimental observations summarised in this review, most clinical effects of valproate can be explained, although much remains to be learned at a number of different levels about the mechanisms of action of valproate. In view of the advances in molecular neurobiology and neuroscience, future studies will undoubtedly further our understanding of the mechanisms of action of valproate.

Valproic acid or valproate, a major and well established first-line antiepileptic (anticonvulsant) drug (AED), is one of the most widely used AEDs in the treatment of different types of epilepsy.^[1,2] Valproate is the trivial name for 2-*n*-propylpentanoic acid (also called *n*-dipropylacetic acid). As a simple branched-chain fatty acid, it differs markedly in structure from all other AEDs in clinical use.

1. Historical Background

Valproate was first synthesised in 1882 by Burton,^[3] but there was no known clinical use until its anticonvulsant activity was fortuitously discovered by Pierre Eymard in 1962 in the laboratory of G. Carraz, as published by Meunier et al.^[4] At that

time, valproate was used as a vehicle to dissolve the active ingredient in testing the anticonvulsant activity of new compounds.^[5] The positive results, whatever the drug and the dose tested, led to the testing of valproate itself and to confirmation that it was effective against drug-induced seizures. The first clinical trials of the sodium salt of valproate were reported in 1964 by Carraz et al.,^[6] and it was first marketed in France in 1967.

2. Overview of Clinical Use

Valproate has been used for the treatment of epilepsy for nearly 35 years and is currently marketed in over 100 countries. Since its introduction into clinical use, valproate has become established

worldwide as a major AED with a wide spectrum of activity against a broad range of seizure disorders. Controlled clinical trials have demonstrated that it has similar efficacy to ethosuximide in the treatment of absence seizures and to carbamazepine, phenytoin and phenobarbital (phenobarbitone) in the treatment of both tonic-clonic and partial seizures.^[7-11] Furthermore, valproate compares favourably with newer AEDs, such as vigabatrin^[12] and oxcarbazepine,^[13] in both efficacy and tolerability.^[14]

Results from numerous clinical trials suggest that valproate probably has the widest spectrum of antiepileptic activity of all established AEDs in both children and adults with epilepsy.^[15,16] In addition to partial and generalised seizures, valproate has demonstrated efficacy in the treatment of syndromes known to be very refractory, such as Lennox-Gastaut syndrome^[17,18] and West syndrome.^[19] This gives valproate special significance for the treatment of patients with mixed seizure types who have highly refractory symptoms.^[14] Furthermore, as a consequence of its broad spectrum of antiepileptic activity and as opposed to many other AEDs, there is no contraindication to the use of valproate in any type of seizure or epilepsy.^[14]

Valproate is tolerated well in most patients.^[20] Most adverse effects are mild to moderate in intensity, and hypersensitivity reactions are rare. A comparison with other widely used AEDs showed that valproate causes fewer neurological adverse effects and fewer skin rashes than phenytoin, phenobarbital and primidone, and its tolerability and safety appear to be similar to that of carbamazepine.^[20] Main areas of concern with valproate are teratogenicity and idiosyncratic liver toxicity. With respect to teratogenicity, recommendations on the use of valproate in women who plan to conceive, such as monotherapy with the lowest effective dose, have lowered this risk, so that with these recommendations valproate does not appear to induce birth defects with any greater frequency than other AEDs.^[20] With respect to idiosyncratic liver toxicity, identification of high-risk patients such as

children under 2 years with severe epilepsy and mental retardation receiving polytherapy has considerably reduced its incidence.^[20]

The present review summarises the major pharmacological effects of valproate that appear to be of importance for its unique antiepileptic efficacy. For a more comprehensive survey of the multiple effects of valproate, including its adverse effects and pharmacokinetics, several previous reviews and monographs are available.^[1,2,15,21,22] Furthermore, the major aspects of the clinical use of valproate, its advantages and limitations and their correlation with pharmacological findings are covered in the review by Perucca^[23] that also appears in this issue of *CNS Drugs*.

3. Epilepsy and Epileptic Seizures

Epilepsy, a common neurological disorder characterised by recurrent spontaneous seizures, is a major, worldwide health problem that affects about 1 to 2% of the population.^[24] Despite progress in understanding the pathogenesis of seizures and epilepsy,^[25] the cellular basis of human epilepsy is only incompletely understood. In the absence of a specific aetiological understanding, approaches to drug therapy of epilepsy must necessarily be directed at the control of symptoms (i.e. the suppression of seizures). Long-term administration of AEDs is the treatment of first choice in epilepsy.

The selection of an AED is based primarily on its efficacy for specific types of seizures according to the international classification of epileptic seizures.^[26] The major categories within this classification are partial and generalised seizures, based on whether a seizure begins locally in a part of one hemisphere, most commonly the temporal lobe, for partial seizures, or is bilaterally symmetrical without local onset for generalised seizures. In addition to this classification of seizures, various types of epilepsy or epileptic syndromes can be identified as characterised by different seizure types, aetiologies, age of onset and EEG features.^[24] More than 40 distinct epileptic syndromes have been identified, making epilepsy a remarkably diverse collection of disorders. Localisation-related

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.